Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study

Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study
Ovarian cancer patients with a BRCA mutation who responded to their last line of platinum-based chemotherapy are more likely to benefit from Rubraca (rucaparib) than those resistant or refractory to platinum treatment, according to new data from the Phase 2 ARIEL2 study. Results were recently presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.
Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

Leave a Comment

Your email address will not be published. Required fields are marked *